Redeye returns with a more in-depth take on the Q2 report. We expect the strong Q2 distributor sales contribution to partly offset its Q3 outlook (driven by Thermo Fisher sales), but we forecast the company to operate at a profit as we advance. We reconsider our direct sales forecast downward, and decrease our base case somewhat.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/